Get started
Author

David Altarac

Nosocomial Outbreak Due to Enterococcus faecium Highly Resistant to Vancomycin, Penicillin, and Gentamicin
1993 · S. Handwerger, B. Raucher, et al. · Clinical Infectious Diseases · 410
Efficacy and safety of sulbactam–durlobactam versus colistin for the treatment of patients with serious infections caused by Acinetobacter baumannii–calcoaceticus complex: a multicentre, randomised, active-controlled, phase 3, non-inferiority clinical trial (ATTACK)
2023 · Keith S Kaye, Andrew F Shorr, et al. · The Lancet Infectious Diseases · 350
Concomitant High-Level Vancomycin and Penicillin Resistance in Clinical Isolates of Enterococci
1992 · S. Handwerger, D. C. Perlman, et al. · Clinical Infectious Diseases · 102
Hiv‐associated Hodgkin disease: A clinical study of 18 cases and review of the literature
1991 · Jay E. Gold, David Altarac, et al. · American Journal of Hematology · 44
Challenges and opportunities in the discovery, development, and commercialization of pathogen-targeted antibiotics
2021 · David Altarac, Michael Gutch, et al. · Drug Discovery Today · 35
PDF
Clinical Outcomes for Patients With Monomicrobial vs Polymicrobial Acinetobacter baumannii-calcoaceticus Complex Infections Treated With Sulbactam-Durlobactam or Colistin: A Subset Analysis From a Phase 3 Clinical Trial
2024 · Sarah M McLeod, Alita A Miller, et al. · Open Forum Infectious Diseases · 19
PDF
Pathogen-Targeted Clinical Development to Address Unmet Medical Need: Design, Safety, and Efficacy of the ATTACK Trial
2023 · Richard R Watkins, Bin Du, et al. · Clinical Infectious Diseases · 12
PDF
Sulbactam–durlobactam for infections caused by Acinetobacter baumannii–calcoaceticus complex – Authors' reply
2023 · Keith S Kaye, Sarah M McLeod, et al. · The Lancet Infectious Diseases · 11
Tuberculosis Treatment Through Directly Observed Therapy in a Large Multisite Methadone Maintenance Treatment Program
1995 · David Altarac, Steven F. Dansky · Journal of Public Health Management and Practice · 4
732. Microbiologic and clinical outcome concordance in the global phase 3 ATTACK trial: Sulbactam-durlobactam (SUL-DUR) versus colistin therapy in patients with Acinetobacter baumannii-calcoaceticus complex (ABC) infections
2022 · David Altarac, Alita Miller, et al. · Open Forum Infectious Diseases · 3
Letter to the editor regarding “Alternative drugs for the treatment of gonococcal infections: old and new” Expert Review of Anti-infective Therapy . 2024. 22(9):753–759
2025 · Alison Luckey, David Altarac, et al. · Expert Review of Anti-infective Therapy · 1
PDF
675. Sulbactam-durlobactam (SUL-DUR) versus colistin therapy in patients with Acinetobacter baumannii-calcoaceticus complex (ABC) infections: A detailed safety review from the pivotal phase 3, global, randomized, active-controlled trial (ATTACK)
2022 · Drew Lewis, Khurram Rana, et al. · Open Forum Infectious Diseases · 1
225. Efficacy and safety of sulbactam-durlobactam are consistent across regions in the global ATTACK phase 3 trial in the treatment of carbapenem-resistant Acinetobacter baumannii-calcoaceticus complex (CRABC) infections
2022 · Alita Miller, Adam B Shapiro, et al. · Open Forum Infectious Diseases · 1
PDF
734. Efficacy of sulbactam-durlobactam (SUL-DUR) versus colistin in patients with extensively drug-resistant (XDR) and pan-drug resistant (PDR) Acinetobacter baumannii-calcoaceticus complex (ABC) infections
2022 · Alita Miller, Sarah McLeod, et al. · Open Forum Infectious Diseases · 1
Sulbactam-Durlobactam Treatment Is Associated with Lower Mortality from Index Acinetobacter Infections in the Attack Phase 3 Registrational Trial
2022 · D. Altarac, A.B. Shapiro, et al. · American Journal of Respiratory and Critical Care Medicine · 1
85. Efficacy of Sulbactam-Durlobactam (SUL-DUR) Compared to Colistin (COL) against Acinetobacter baumannii-calcoaceticus Complex (ABC) Monomicrobial and Polymicrobial Infections in a Phase 3 Trial
2023 · Alita Miller, Sarah McLeod, et al. · Open Forum Infectious Diseases
PDF
AIDS risk behavior among women in methadone treatment
1996 · Veronica Catan, F Schilling, et al.
Works count: 17
Citation count: 995
H-index: 8
I10-index: 8
Year
Topic
Type